Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer

[1]  W. Sause.  The role of radiotherapy in non-small cell lung cancer. , 1999, Chest.

[2]  B. Bergman,et al.  Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. , 1998, European journal of cancer.

[3]  R. Greil,et al.  Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial. , 1997, European journal of cancer.

[4]  L. Billingham,et al.  26 Mitomycin, ifosfamide and cisplatin (MIC) in non-small cell lung cancer (NSCLC): 3. Results of a randomised trial evaluating palliation & quality of life , 1997 .

[5]  Sørensen Jb,et al.  Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: a review. , 1997 .

[6]  W. Bezwoda,et al.  Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Shepherd,et al.  Phase I trial of gemcitabine and cisplatin in advanced non-small cell lung cancer: a preliminary report. , 1996, Lung cancer.

[8]  R. Comis,et al.  New chemotherapy agents in the treatment of advanced non-small cell lung cancer: an update including data from the Seventh World Conference on Lung Cancer. , 1995, Lung cancer.

[9]  H. Hansen,et al.  Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Pujol,et al.  Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer. , 1994, British Journal of Cancer.

[11]  J. Herndon,et al.  Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Kerpel-Fronius,et al.  Ifosfamide (IFO)+vinorelbine (VRL) as treatment for advanced, non operable non small cell lung cancer (NSCLC) , 1994 .

[13]  S. Kaasa,et al.  Polychemotherapy in advanced non small cell lung cancer: a meta-analysis , 1993, The Lancet.

[14]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[15]  R. Figlin,et al.  Supportive care versus supportive care and combination chemotherapy in metastatic non‐small cell lung cancer. Does chemotherapy make a difference? , 1989, Cancer.

[16]  R. Folman,et al.  The role of chemotherapy in non-small cell lung cancer: the community perspective. , 1988, Seminars in oncology.

[17]  R. Feld.  Quality of life in patients with non-small cell lung cancer treated with chemotherapy. , 1987, European journal of cancer & clinical oncology.

[18]  P. Bartsch,et al.  Quality of life of inoperable non-small cell lung carcinoma. A randomized phase II clinical study comparing radiotherapy alone and combined radio-chemotherapy. , 1987, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  N. Aaronson,et al.  Vindesine, cisplatin, and bleomycin combination chemotherapy in non-small cell lung cancer: survival and quality of life. , 1986, European journal of cancer & clinical oncology.

[20]  A McMurray,et al.  Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Groth,et al.  51Cr-EDTA clearance determined by one plasma sample. , 1981, Clinical physiology.

[22]  G. Scagliotti,et al.  Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Holland,et al.  Do oncologists have an increasing interest in the quality of life of their patients? A literature review of the last 15 years. , 1997, European journal of cancer.

[24]  H. Hansen,et al.  Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: a review. , 1997, Seminars in oncology.

[25]  D. Richel,et al.  Clinical, toxicological and pharmacological aspects of gemcitabine. , 1996, Cancer treatment reviews.

[26]  T. le Chevalier,et al.  Chemotherapy of stage IIIB and IV non-small-cell lung cancer. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  S. Kaasa,et al.  The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. , 1994, European journal of cancer.

[28]  M. Sullivan,et al.  Quality of life during chemotherapy for small cell lung cancer. II. A longitudinal study of the EORTC Core Quality of Life Questionnaire and comparison with the Sickness Impact Profile. , 1992, Acta oncologica.

[29]  M. Sullivan,et al.  Quality of life during chemotherapy for small cell lung cancer. I. An evaluation with generic health measures. , 1991, Acta oncologica.

[30]  P. Maasilta,et al.  Quality of life assessment during chemotherapy for non-small cell lung cancer. , 1990, European journal of cancer.

[31]  S. Kaasa,et al.  Toxicity, physical function and everyday activity reported by patients with inoperable non-small cell lung cancer in a randomized trial (chemotherapy versus radiotherapy). , 1988, Acta oncologica.

[32]  S. Kaasa,et al.  Psychosocial well-being of patients with inoperable non-small cell lung cancer. The importance of treatment- and disease-related factors. , 1988, Acta oncologica.

[33]  M. Bayssas,et al.  Vindesine: a new vinca alkaloid. , 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.